NUVL - Company ID 0001861560
Nuvalent, Inc. trades as NUVL and has a market capitalization of $8.64 B, making it the #1049 largest US-listed company by market value. This page tracks Nuvalent, Inc. through 529 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-05-29
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Quarterly report | 10-Q | 2026-05-07 |
| Major company event | 8-K | 2026-05-07 |
| Insider trade | 4 | 2026-05-06 |
| SCHEDULE 13G/A | - | 2026-05-06 |
| Insider trade | 4 | 2026-05-05 |
| Insider trade | 4 | 2026-05-01 |
| Insider trade | 4 | 2026-05-01 |
| Insider sale notice | 144 | 2026-04-30 |
CAMBRIDGE, Mass. , May 7, 2026 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL ), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today outlined pipeline progress, reiterated key anticipated milestones, and reported first quarter 2026 financial results.
"If zidesamtinib is approved, a first commercial launch in 2026 would be a transformative moment for Nuvalent and the first step towards ...
OnTarget 2026 delineates Nuvalent's 3-year operating plan towards bringing new, potential best-in-class medicines to patients with cancer.
The largest companies sharing Nuvalent, Inc.'s SEC industry classification (pharmaceutical preparations).
Nuvalent, Inc. (NUVL) has a market capitalization of $8.64 B as of 2026-05-29, ranking #1049 among US-listed companies.
In its latest fiscal year Nuvalent, Inc. reported a net loss of $425.40M.